8-K: Aquestive Therapeutics Provides Investor Update, Highlights Progress on Key Pipeline Assets

Aquestive Therapeutics provides an update on its pipeline, including Anaphylm, Libervant, and AQST-108, along with financial guidance for 2024.

Summary

• Aquestive Therapeutics is a pharmaceutical company focused on developing and commercializing innovative medicines using its proprietary PharmFilm technology.
• The company's lead product candidate, Anaphylm, an epinephrine sublingual film for anaphylaxis, has completed adult clinical studies and is on track for an NDA submission by Q1 2025.
• Anaphylm has shown rapid absorption and consistent pharmacokinetics, with a safety profile comparable to standard of care epinephrine auto-injectors.
• The company anticipates the U.S. epinephrine market to reach approximately $2 billion by 2031.
• Libervant, a diazepam buccal film, is approved for patients aged 2-5, with plans to launch for ages 6-11 after FDA approval and for ages 12 and up after the expiration of an orphan drug exclusivity period in January 2027.
• AQST-108, an epinephrine topical gel, is being developed for alopecia areata, with a Phase 2a clinical study planned.
• Aquestive expects total revenues of approximately $57 to $60 million and a non-GAAP adjusted EBITDA loss of approximately $20 to $23 million for 2024.
• The company's cash runway has been extended into 2026 following a $77.5 million public offering in Q1 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical results for Anaphylm, a clear path to NDA submission, and a diversified pipeline. The company has also secured funding to extend its cash runway. However, there are some risks and delays, which temper the overall sentiment.

Positives

• Anaphylm has shown positive clinical results, meeting all predetermined primary and secondary endpoints in adult studies.
• Anaphylm's rapid absorption and consistent pharmacokinetics are comparable to epinephrine auto-injectors.
• The company has a diversified pipeline with multiple product candidates in development.
• Aquestive has a strong intellectual property portfolio with over 150 patents worldwide.
• The company has established manufacturing capabilities for oral thin film products.
• The company has a clear path to NDA submission for Anaphylm by Q1 2025.
• The company has secured funding to extend its cash runway into 2026.

Negatives

• The company is experiencing a non-GAAP adjusted EBITDA loss of approximately $20 to $23 million for 2024.
• Libervant's launch for patients 12 and up is delayed until January 2027 due to orphan drug market exclusivity of a competitor's product.
• The company faces risks associated with the regulatory approval process for its product candidates.
• There are risks associated with commercializing new products and developing sales and marketing capabilities.

Risks

• There are risks associated with the development and regulatory approval of Anaphylm, AQST-108, and Libervant.
• The company may face delays or changes in the timing, cost, and success of its clinical trials.
• There is a risk that the FDA may require additional clinical studies for approval of Anaphylm.
• The company may not overcome the orphan drug market exclusivity for Libervant for patients aged six and older until January 2027.
• There are risks associated with commercializing new products, including market acceptance and competition.
• The company needs sufficient capital and cash resources to fund its operations and commercialization activities.
• There are risks related to intellectual property rights and potential infringement claims.

Future Outlook

The company anticipates continued progress on its pipeline, with a focus on Anaphylm's NDA submission, Libervant's commercial expansion, and the advancement of AQST-108. The company expects to launch Anaphylm in 2026, Libervant for ages 12 and up in 2027, and AQST-108 in 2028 or later.

Management Comments

• The company is focused on advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies.
• The company believes Anaphylm has the potential to be the first and only oral administration of epinephrine and accepted as an alternative to existing standards of care.
• The company is confident in its ability to execute its growth plan and deliver value to shareholders.

Industry Context

This announcement comes as the pharmaceutical industry continues to focus on innovative drug delivery methods and addressing unmet medical needs. The development of an oral epinephrine product like Anaphylm could be a significant advancement in the treatment of anaphylaxis. The company is also addressing the need for better treatments for epilepsy and alopecia areata.

Comparison to Industry Standards

• Aquestive's Anaphylm is unique as it is an oral thin film, unlike the current standard of care which is epinephrine auto-injectors (EAIs) such as EpiPen and Auvi-Q.
• The company's data shows Anaphylm has a faster median Tmax of 12 minutes compared to EpiPen (20 minutes), Auvi-Q (30 minutes), and manual intramuscular injection (50 minutes).
• The company's PharmFilm technology is a differentiator, with over 2 billion doses distributed for patient use, and is used in multiple FDA approved products.
• The company's pipeline includes Libervant, which is a buccal film for epilepsy, and AQST-108, a topical gel for alopecia areata, which are both novel approaches to these conditions.
• The company's financial guidance for 2024 indicates a loss, which is not uncommon for companies in the development stage, but the company has secured funding to extend its cash runway into 2026.

Stakeholder Impact

• Shareholders may benefit from the potential commercial success of Anaphylm, Libervant, and AQST-108.
• Patients may benefit from the availability of new treatment options for anaphylaxis, epilepsy, and alopecia areata.
• Employees may benefit from the company's growth and success.
• Customers may benefit from the company's innovative products and services.

Next Steps

• The company plans to hold a pre-NDA meeting with the FDA for Anaphylm in Q4 2024.
• The company plans to file the NDA for Anaphylm in Q1 2025.
• The company plans to launch Libervant for ages 6 to 11 after FDA approval.
• The company plans to commence a Phase 2a clinical study for AQST-108 for alopecia areata after alignment with the FDA.

Key Dates

Keywords

Anaphylm, epinephrine, Libervant, AQST-108, PharmFilm, anaphylaxis, epilepsy, alopecia areata, oral thin film, FDA, clinical trials, NDA, regulatory approval, pharmaceuticals